Drug intelligence / Profile preview

e-Voke

Development stage: Unknown
Lead developer: Nicoventures
Modality: Small Molecules
Administration: Inhalation

Overview

e-Voke is an electronic cigarette (e-cigarette) developed by Nicovations, a subsidiary of British American Tobacco (BAT). It is designed as a nicotine delivery system to aid in smoking cessation and the reduction of tobacco consumption. Unlike the Voke inhaler, which is a pressurized nicotine delivery device, e-Voke is a battery-powered electronic device that vaporizes a nicotine-containing solution for inhalation. In late 2015, e-Voke became the first e-cigarette to be granted a medicines license by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), allowing it to be marketed as a regulated therapeutic option for smokers looking to quit or reduce their tobacco consumption.

Brand names: e-Voke

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on e-Voke.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on e-Voke.

Explore the full profile